Clinical trial Recruiting at 9 sites Observational Ages 18 and up

Lemborexant for insomnia in people with psychiatric conditions

Official title: A Multicenter, Prospective, Single-Arm, Observational Study on Effectiveness and Safety of Lemborexant on Insomnia Patients With Psychiatric Disorders

Run by Shanghai Mental Health Center · NCT07417813 · Data updated 2026-11-12

We will try lemborexant for 8 weeks in adults with psychiatric disorders who have insomnia to see if it helps them sleep better and is safe.

More Insomnia trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment121 (estimated)
SponsorShanghai Mental Health Center
Academic / other
Locations9 sites (Suzhou, Jiangsu and 8 other locations)
StatusRecruiting
StartedJanuary 24, 2026
Main results expectedAugust 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 18, 2026
Trial IDNCT07417813 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who meet DSM-5 criteria for a psychiatric disorder, have an ISI score ≥11, can commit to roughly 8 weeks of treatment and follow-up, and whose clinicians plan to start lemborexant are the intended participants.

Probably not a fit

Patients in an acute psychiatric episode or with unstable psychotropic dosing, high suicide risk, narcolepsy, severe liver failure, pregnancy or breastfeeding, recent DORA use, or concurrent use of multiple benzodiazepine-receptor agonists are unlikely to benefit or be appropriate for this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, single-arm observational study enrolling about 121 adults with psychiatric disorders and an Insomnia Severity Index (ISI) score of 11 or higher. Participants will receive lemborexant tablets for 8 weeks with scheduled scale-based assessments (including ISI and visual analogue scales) and safety monitoring for adverse events. The study is intended to capture real-world effectiveness and tolerability in a clinically diverse psychiatric population rather than a randomized comparison. Data will be collected across several hospitals in Shanghai and Jiangsu and used to inform clinical use of lemborexant in patients with comorbid psychiatric illness.

Why it matters

Potential benefit: If successful, the study could show that lemborexant improves sleep in people with psychiatric disorders and offers a safer alternative to benzodiazepine-type sleep drugs.

How similar studies have gone: Other randomized trials of lemborexant and similar dual orexin receptor antagonists have shown efficacy for primary insomnia, but real-world data specific to patients with comorbid psychiatric disorders remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Aged 18 years and above, regardless of gender;
2. Meet the DSM-5 diagnostic criteria for mental disorders (any type);
3. Insomnia Severity Index (ISI) score ≥11;
4. Have at least 7 hours of sleep time available;
5. Able to complete the 2-month scale assessment and follow-up plan;
6. Voluntarily sign the informed consent form;
7. Intend to receive lemborexant treatment as judged by the clinicians

Exclusion Criteria:

1. Mental disorder is in the acute phase as judged by clinical assessment, or the dose of other psychotropic drugs cannot be stabilized during the study;
2. Concurrent use of ≥2 types of benzodiazepine receptor agonists (BZRAs) as insomnia treatment drugs;
3. Previous continuous use of dual orexin receptor antagonist (DORA)-type drugs for \>1 week;
4. Clear suicide attempt/plan or high suicide risk as judged by the researcher;
5. Pregnant or lactating women;
6. Patients with narcolepsy;
7. Patients with severe hepatic insufficiency;
8. Currently accompanied by severe or unstable diseases of cardiovascular, respiratory, digestive and other systems;
9. Other conditions deemed unsuitable for participation by the researcher

Where it's running

  • Suzhou GuangJi Hospital
    Suzhou, Jiangsu, China
    Recruiting
  • Xuzhou Oriental People's Hospital
    Xuzhou, Jiangsu, China
    Recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Shanghai Pudong New Area Mental Health Center
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Shanghai Fengxian District Mental Health Center
    Shanghai, Shanghai Municipality, China
    Recruiting
Show 3 more locations
  • Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.